



Cite this: RSC Adv., 2016, 6, 15670

## Enhanced $Zn^{2+}$ ion-sensing behavior of a benzothiazole derivative on encapsulation by $\beta$ -cyclodextrin†

Rajathi Queen Paulpandi,<sup>a</sup> Sivaraj Ramasamy,<sup>a</sup> Mosae Selvakumar Paulraj,<sup>a</sup> F. Guillermo Díaz Baños,<sup>c</sup> G. Villora,<sup>d</sup> José P. Cerón-Carrasco,<sup>e</sup> Horacio Pérez-Sánchez<sup>\*e</sup> and Israel V. Muthu Vijayan Enoch<sup>\*ab</sup>

We report, in this paper, a benzothiazole derivative which shows selective binding of zinc ions among a pool of metal ions and the enhanced selectivity of the same metal ion by the derivative in its  $\beta$ -cyclodextrin bound form. The  $Zn^{2+}$  ion binding is studied using UV-visible absorption and fluorescence spectroscopy. The stoichiometry and binding mode of the benzothiazole derivative- $\beta$ -cyclodextrin complex are determined using 1D and 2D NMR spectroscopic analysis. The cyclodextrin molecule slides over the benzothiazole derivative and resides above the aminomethyl group linking the benzothiazole and dihydroxyphenyl moieties. The site of binding of the  $Zn^{2+}$  ion with the compound remains the same both in the compound's free and cyclodextrin-complexed forms. Molecular modeling studies were also carried out in order to obtain more details about the cyclodextrin-compound and  $Zn^{2+}$ -compound interactions, and their results are in close agreement with obtained experimental data.

Received 14th January 2016  
 Accepted 27th January 2016

DOI: 10.1039/c6ra01202g  
[www.rsc.org/advances](http://www.rsc.org/advances)

### Introduction

Mobile zinc is an essential factor in many biological processes such as brain function, physiological processes, such as Alzheimer's disease, epilepsy, stroke, and infantile diarrhea.<sup>1</sup> Mobile  $Zn^{2+}$  ions are associated with biological processes including signaling and regulation,<sup>2</sup> nucleation of protein self-assembly,<sup>3</sup> and modification of cellular metabolism.<sup>4</sup> Essential tasks of the central nervous system, prostate, and pancreas are performed by mobile zinc.<sup>5</sup> Alterations to prostatic zinc trafficking are linked to the onset and progression of prostate cancer.<sup>6</sup> Detection and quantification of mobile  $Zn^{2+}$  ion in solution therefore draws attention. Zinc is spectroscopically silent and various fluorescent chemosensors of  $Zn^{2+}$  at physiological pH have been reported.<sup>7</sup>

The cyclic oligosaccharide,  $\beta$ -cyclodextrin, with its tapered-cone-like structure and a cavity able to accommodate guest molecules of appropriate size and shape, are known to alter the fluorescence emission of complexed guest molecules. Fluorescence enhancement is the most observed property on such host-guest complex formation,<sup>8</sup> whereas quenching of fluorescence also is scarcely reported.<sup>9</sup> Knowing the exact structure of the host-guest complex is of paramount importance in understanding the alteration of the physicochemical properties and the spectroscopic behavior of the guest molecules. Benzothiazoles are pharmacologically active molecules and their derivatives have been prepared using a wide range of methodologies.<sup>10</sup> Although the literature is abundant with reports on the structure of  $\beta$ -cyclodextrin complexes, reports on relationship between the host-guest complex structure and the metal ion binding activity of the complexes are very scarce. In this paper, we report the structure of the  $\beta$ -CD complex of a benzothiazole derivative based on experimental and theoretical studies and the molecule's enhanced  $Zn^{2+}$  ion binding behavior in the  $\beta$ -CD-bound form.

### Results and discussion

#### Compound 1- $\beta$ -cyclodextrin complex

Compound 1 was formed on the reduction of the Schiff base formed from the reaction of 2-aminobenzothiazole and 3,4-dihydroxybenzaldehyde [for the  $H^1$  and  $C^{13}$  NMR spectra of compound 1 see ESI 1(a) and (b)†]. We investigated the fluorescence properties of 1 in aqueous  $\beta$ -cyclodextrin medium. Keeping

<sup>a</sup>Department of Chemistry, Karunya University, Coimbatore 641114, Tamil Nadu, India. E-mail: drisraelenoch@gmail.com

<sup>b</sup>Department of Nanosciences & Technology, Karunya University, Coimbatore 641114, Tamil Nadu, India

<sup>c</sup>Department of Physical Chemistry, University of Murcia, Campus of Espinardo, E-30071, Murcia, Spain

<sup>d</sup>Department of Chemical Engineering, Faculty of Chemistry, Regional Campus of International Excellence "Campus Mare Nostrum", University of Murcia, Campus of Espinardo, E-30071, Murcia, Spain

<sup>e</sup>Bioinformatics and High Performance Computing Research Group, Universidad Católica San Antonio de Murcia (UCAM), Spain. E-mail: hperez@ucam.edu

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ra01202g



the concentration of **1** constant,  $\beta$ -CD solution was added in aliquots so that the concentration of  $\beta$ -CD increased stepwise up to  $1 \times 10^{-2}$  mol dm $^{-3}$ . The structureless band of the absorption spectrum of **1** in aqueous solution was centered at 261 nm. This band corresponds to the  $n-\pi^*$  transition of **1**. Addition of  $\beta$ -CD lead to a continuous blue shift of absorption band, and at the final concentration level of  $\beta$ -CD, the absorption wavelength of the band envelope was 256 nm. The gradual blue shift at each addition of  $\beta$ -CD is a result of the change in the microenvironment of **1** as it dislodges from the polar water solvent cage to a non-polar surrounding. This occurs due to the entry of **1** into the hydrophobic cavity of  $\beta$ -CD. The second observation was that the absorption intensity got (or absorbance) continuous enhanced until the largest concentration ( $1 \times 10^{-2}$  mol dm $^{-3}$ ) was reached (hyperchromic shift). This is a result of enhanced absorption of light, the free movement of electrons into various energy levels,<sup>11</sup> and hence the enhanced transition probability of the delocalization of electrons in **1**. The complex formation of **1** with  $\beta$ -CD was further followed using steady state fluorescence spectroscopy (exciting at the absorption wavelength maximum) of the same samples used for recording UV-visible spectra. The fluorescence band at 300 nm of **1** in aqueous solution got enhanced at the addition of  $\beta$ -CD (Fig. 1(a)).





Fig. 1 (a) Fluorescence spectra of **1** at various added amounts of  $\beta$ -CD  
(b) Benesi–Hildebrand plot of the **1**– $\beta$ -CD 1 : 1 complex.

This enhancement of fluorescence is more pronounced than absorption. Hence, we used the fluorescence spectral intensities for doing the Benesi–Hildebrand plot (Fig. 1(b)), which was employed to derive the stoichiometry and binding constant of **1**– $\beta$ -CD complex. The binding equilibrium is given by



and the corresponding equation governing the binding event is<sup>12</sup>

$$\frac{1}{I - I_0} = \frac{1}{I' - I_0} + \frac{1}{(I' - I_0)K[\beta - \text{CD}]} \quad (2)$$

where  $I$ ,  $I_0$ ,  $I'$  are the fluorescence intensities of **1** at various concentration of  $\beta$ -CD in water, and at the highest concentration of  $\beta$ -CD respectively.  $K$  is the binding constant. The plot of  $1/[I - I_0]$  vs.  $1/[I' - I_0]$  was linear and the calculated binding constant was  $79.96 \pm 8$  M $^{-1}$ . The linearity of the plot means that the host–guest complex was 1 : 1. The magnitude of the binding constant of a 1 : 1 complex of a  $\beta$ -CD inclusion complex is usually a few hundreds, if the complex formed is a strong one.<sup>13</sup> Hence, compound **1** should have formed a weaker bound host–guest complex.

In order to comprehend the mode of encapsulation of **1** by  $\beta$ -CD, we analyzed the chemical shift of various protons of the **1**– $\beta$ -CD complex and free  $\beta$ -CD.<sup>11</sup> The changes of proton NMR chemical shifts on complex formation are shown in Fig. 2 and the chemical shift values are given in Table 1.

Further evidence to the inference, that the  $\beta$ -CD covered up the  $-\text{NH}-\text{CH}_2-$  units, was gained from an insight into the 2D rotating-frame overhauser effect spectrum (2D ROESY) of the **1**– $\beta$ -CD complex.

The partial ROESY spectrum (Fig. 3(a)) shows off-diagonal peaks, indicating the close proximity of the H-5 and H-3 protons (ppm and ppm respectively) of  $\beta$ -CD and methylene protons of the  $-\text{NH}-\text{CH}_2-$  bridging the benzothiazole and the dihydroxybenzene moieties (for the full 2D ROESY spectrum, see ESI 3†). The H-3, H-5 protons are lined in the inner rim of  $\beta$ -CD and hence the above observation means that the  $\beta$ -CD molecule slips over the aromatic rings of **1** to stand at the centre of the molecule, completely covering up the  $-\text{NH}-\text{CH}_2-$  unit. Off-diagonal cross peaks were not obtained in the aromatic region of the spectrum and hence the encapsulation of the guest molecule at its edges are found unlikely. It further means




Fig. 2 Comparison of the  $\text{H}^1$  NMR spectra of free compound **1** and **1**– $\beta$ -CD complex.



**Table 1**  $^1\text{H}$  NMR chemical shifts of free compound **1** and **1**– $\beta$ -CD complex

Protons	Free compound <b>1</b>	<b>1</b> – $\beta$ -CD complex
–NH–	5.710	5.824
–CH <sub>2</sub> –	4.791	4.835
OH		
a	7.254	7.211
Proton 'a'		
b	6.956	6.904
Proton 'b'		

that the two phenol –OH groups are not encapsulated by  $\beta$ -CD and are free for binding to metal ions, which is discussed in the next sections. The proposed structure of the **1**– $\beta$ -CD complex is represented in Scheme 1.

In order to understand how **1** interacted with  $\beta$ -CD, docking simulations were carried out. Additionally, the structural information about the binding pose obtained by docking is shown in Fig. 3(b). We can see that **1** binds tightly into  $\beta$ -CD's internal cavity. These results are in agreement with  $^1\text{H}$  2D-ROESY data obtained. Also, it is clear that with this conformation, **1** binds tightly into  $\beta$ -CD's hydrophobic core.

### Cation-binding property of compound **1**

In order to investigate the application of **1** as a chemosensor, the metal ion binding characteristics were investigated towards metal cations which are relevant to biology and present in human body, *viz.*, and the physiological pH (7.4) was maintained and the buffer used was HEPES. Although the absorption spectra of **1** in the presence of various added metal ions were not significantly different (ESI 4†), the fluorescence spectra (Fig. 4(a)) showed interesting result revealing the selectivity of **1**. The changes of the fluorescence of **1** on metal ion addition were more pronounced than that of the absorption spectrum. The fluorescence spectrum showed a quenching behavior when each of the metal ion from the pool of different metals was added. However, at the addition of  $\text{Pb}^{2+}$  or  $\text{Zn}^{2+}$ , the fluorescence of **1** got enhanced. In particular, addition of  $\text{Zn}^{2+}$  made the spectral band at 400 nm enhance in intensity by 2.5 times, which made the **1**– $\text{Zn}^{2+}$  spectrum stand out. The fluorescence spectrum of **1** showed two prominent bands, *viz.*, 340 nm and 410 nm. The shorter wavelength band seemingly contributed by the dihydroxy benzene moiety of **1** is the one which shows enhancement, whereas the longer wavelength band remains unaltered. This implies that the phenolics –OH groups are involved in the metal ion binding. A comparison of the intensities of fluorescence is shown in Fig. 4(b).





Fig. 3 (a) Partial 2D ROESY spectrum of compound **1**– $\beta$ -CD complex. (b) Docking results obtained for the complexation of **1** with  $\beta$ -CD.



Scheme 1 Structure of the 1 : 1 host–guest complex.

Fig. 5 illustrates the optimized DFT structures of **1**– $\text{Zn}^{2+}$  and **1**– $\text{Ca}^{2+}$  complexes as well as the free form of **1**. As showed, the intramolecular hydrogen bonding established between both hydroxyl groups are disrupted when moving from the free form to the corresponding complexes. This is the logical consequence of the  $\text{Zn}^{2+}$  and  $\text{Ca}^{2+}$  coordination, which is governed by the interactions with the oxygen atoms and force the twist of one of the –OH groups. The performed simulations






Fig. 4 (a) Fluorescence spectra of **1** with various added metal ions in HEPES (b) fluorescence intensities of **1** with various added metal ions in HEPES.




Fig. 5 Optimized structures of free **1**, **1**- $\text{Ca}^{2+}$  and **1**- $\text{Zn}^{2+}$  represented in ball and sticks. Color code: white for hydrogen, grey for carbon, blue for nitrogen, red for oxygen, light yellow for sulfur, dark yellow for calcium and purple for zinc.

reveal such process is favored in the case of  $\text{Zn}^{2+}$ , with an associated equilibrium constant of 647.63, significantly larger than the obtained for  $\text{Ca}^{2+}$ , which is only 0.06. The optimized  $\text{Zn}^{2+}$ -O (2.08 Å) and  $\text{Ca}^{2+}$ -O (2.44 Å) distances match to the observed relative energy pattern: the shorter the ligand-cation bond, the stronger the interaction. That dissimilarity leads to a larger O- $\text{Zn}^{2+}$ -O bond angle compared to the obtained for O- $\text{Ca}^{2+}$ -O, 75.5° and 63.4°, respectively. Consequently, both  $K_{\text{eq}}$  and geometries stand for the larger stability of **1**- $\text{Zn}^{2+}$  compared to its **1**- $\text{Ca}^{2+}$  counterpart since the ligand better accommodate the former cation in their structure. This finding hints the potential ability of DFT calculations to predict the relative stability order for **1**-like complexes.

The stoichiometry of the **1**- $\text{Zn}^{2+}$  complex was obtained from the Job's plots made using the data obtained from the

concentration dependent changes of the absorbance and the fluorescence intensity. The spectra are shown in ESI 5(a) and (b)† respectively. The Job's plots of the absorbance or the intensity of fluorescence at 360 nm vs. the molar fraction of **1**, with a constant total concentration are shown in Fig. 6(a) and (b).

The maximum absorbance or the fluorescence intensity was found when the molar fraction was 1.0. This indicated that the **1**- $\text{Zn}^{2+}$  complex formed in a 1 : 1 fashion. Based on the





Fig. 6 (a) Job's plot of the **1**- $\text{Zn}^{2+}$  complex formation, made using absorbance data (b) Job's plot of the **1**- $\text{Zn}^{2+}$  complex formation, made using fluorescence intensities.



Scheme 2 Structure of the compound **1**- $\text{Zn}^{2+}$  complex.

above observation, the binding pattern of the **1**–Zn<sup>2+</sup> complex can be depicted as in Scheme 2.

### Zn<sup>2+</sup> binding by compound **1**– $\beta$ -CD complex

Metal ion binding experiments in a fashion, similar to the previous section, was done using **1**– $\beta$ -CD complex at the




Fig. 7 (a) Absorption spectra of **1**– $\beta$ -CD with various added metal ions (b) fluorescence spectra of **1**– $\beta$ -CD with various added metal ions (c) comparison of the fluorescence intensities of various metal ion-added **1** in the presence of aqueous  $\beta$ -CD.

saturation concentration of  $\beta$ -CD. Zn<sup>2+</sup> selectivity was observed similar to the one seen in aqueous medium. However, this time the fluorescence intensity of the Zn<sup>2+</sup> ion-added **1**– $\beta$ -CD solution showed a four-fold enhancement. The absorption and fluorescence spectral titrations of **1** against various metal ions are shown in Fig. 7(a) and (b) respectively. Fig. 7(c) shows a comparison of the fluorescence intensities of various metal ion-added **1** in the presence of aqueous  $\beta$ -CD. The Job's plot made of the binding of Zn<sup>2+</sup> to the **1**– $\beta$ -CD complex, using absorption and fluorescence spectral data, are shown in Fig. 8(a) and (b) respectively. The absorption and the fluorescence spectra of the binding titrations of Zn<sup>2+</sup> against **1**– $\beta$ -CD complex in HEPES are shown in ESI 6(a) and (b) respectively.

The effect of pH on the fluorescence intensity of **1** at 420 nm is shown in ESI 7.† It shows the fluorescence intensity reaches saturation above pH 6 and the intensity is stable above this pH




Fig. 8 (a) Job's plot of the **1**–Zn<sup>2+</sup> complex formation, made using absorbance (b) Job's plot of the **1**–Zn<sup>2+</sup> complex formation, made using fluorescence intensities.






Fig. 9 Competitive binding of  $Zn^{2+}$  to (a) **1** and (b)  $1-\beta$ -CD complex in the presence of other metal ions.

up to pH 8. Hence, the sensor is quite stable under the physiological pH.

The influence of other metal ions on the  $1-Zn^{2+}$  binding was studied at  $1 \times 10^{-5}$  mol dm $^{-3}$  concentration of the metal ions. The fluorescence got enhanced when  $Zn^{2+}$  was added in the presence of each of the other metal ions (Fig. 9(a)). This enhancement of fluorescence was similar to that occurred when  $Zn^{2+}$  ion alone was added. An experiment on the  $1-\beta$ -CD complex –  $Zn^{2+}$  ion binding showed similar result, however, with an enhanced selectivity for  $Zn^{2+}$  by **1** in its  $\beta$ -CD complexed form (Fig. 9(b)). Hence, the  $\beta$ -CD encapsulation resulted in a better  $Zn^{2+}$  ion sensing. The log  $K$  values of the  $1-Zn^{2+}$  and  $1-\beta$ -CD- $Zn^{2+}$  binding were  $8.9 \pm 0.2$  and  $8.8 \pm 0.2$  respectively. This result suggests that the enhancement of fluorescence of **1** by  $\beta$ -CD encapsulation contributed to the enhanced sensing of  $Zn^{2+}$ .

We carried out titrations of **1** ( $1 \times 10^{-5}$  mol dm $^{-3}$ ) against  $Zn^{2+}$ , adding 0 to 110 equivalents of  $Zn^{2+}$  in water and aqueous  $\beta$ -CD media. Saturation point was reached at 110 equivalents of  $Zn^{2+}$ . The plots of relative intensity *versus* the concentration of  $Zn^{2+}$  ion in low ranges in water and in  $\beta$ -CD are shown in Fig. 10(a) and (b) respectively. The detection limits of  $Zn^{2+}$  by **1** in water and in  $\beta$ -CD are  $8.21 \times 10^{-8}$  and  $8.71 \times 10^{-8}$  mol dm $^{-3}$  respectively.




Fig. 10 Relative fluorescence intensity of (a) **1** and (b)  $1-\beta$ -CD complex as a function of the  $Zn^{2+}$  concentration (0 to  $9 \times 10^{-8}$  mol dm $^{-3}$ ).

## Conclusions

A novel fluorescent sensor is designed and synthesized by coupling benzothiazole and dihydroxybenzene units. The compound exhibits high selectivity in the detection of  $Zn^{2+}$  over other biologically relevant metal ions with a turn-on fluorescence effect. Molecular modeling calculations explain this result due to the fact that distance  $Zn^{2+}$ -O is the shortest one, and the shorter the ligand-cation bond, the stronger the interaction. The compound forms a 1 : 1 host-guest complex with  $\beta$ -cyclodextrin.  $\beta$ -Cyclodextrin encapsulates the  $-NH-CH_2-$  moiety of the compound, and this result is also predicted by the application of molecular modeling techniques. The host-guest complex selectively binds with  $Zn^{2+}$  similar to the free compound in solution with enhanced sensitivity and selectivity. It gives indirect evidence that the two phenolic groups are involved in the  $Zn^{2+}$  binding as the  $\beta$ -cyclodextrin molecule covers up the  $-NH-CH_2-$  group of the benzothiazole moiety. Partial encapsulation by  $\beta$ -cyclodextrin can thus enhance the sensing of metal ions in solution provided the binding site of the chemosensor is not hidden from the possible binding of  $Zn^{2+}$  ions.



The range of selectivity and the sensitivity shown by sensors towards metal ions and other analytes are varied.<sup>14</sup> In the present study, although the benzothiazole derivative shows a lesser efficiency than few of the reported  $Zn^{2+}$  ion sensors,<sup>15</sup> it is notable that  $\beta$ -CD enhances the efficiency of sensing. Similar study can be done on already existing chemosensors (applying fluorescence-based methods and showing high selectivity) by using CD complex formation.


## Materials and methods

### Reagents and instruments

2-Aminobenzothiazole, 3,4-dihydroxybenzaldehyde, and  $\beta$ -cyclodextrin were purchased from sigma Aldrich, Bangalore. The sulfates of lead, calcium, magnesium, manganese, nickel, copper, aluminium, iron and zinc were the product of Sigma Aldrich, Bangalore. Triply distilled water was used throughout and the buffer used was HEPES (pH 7.4). The UV-visible absorption spectra were measured on a Jasco V-630 spectrophotometer (Japan) using 1 cm path length quartz cuvettes. Absorption measurements were done keeping the corresponding reference solution without the fluorophore. Fluorescence spectra were recorded on a Jasco FP-8300 spectrofluorometer (Japan). The  $^1H$  and  $^{13}C$  NMR spectra were recorded on a Bruker 400 MHz (USA) spectrometer with the use of tetramethylsilane as the internal standard and dimethyl sulfoxide (DMSO) as the solvent.

### Synthesis of 4-[(1,3-benzothiazole-2-ylamino)methyl]benzene-1,2-diol (compound 1)

Compound **1** was prepared by treating a solution of 3,4-dihydroxybenzaldehyde (0.2 g, 0.001 mmol) in ethanol (10 ml) with the solution of 2-aminobenzothiazole (0.15 g, 0.001 mmol) in ethanol (10 ml) at 60 °C in the presence of NaOH. The mixture was stirred and refluxed for 6 hours to get a yellow coloured product (melting point, 123 °C). The product, 4-(1,3-benzothiazol-2-ylamino)methylbenzene-1,2-diol was reduced using  $NaBH_4$  to get final yellow coloured solid. The solid was collected by filtration and recrystallized from ethanol (melting point: 123 °C). The formation of products was followed using thin-layer chromatography (TLC) on glass plats coated with  $SiO_2$  GF254. The scheme of synthesis of compound **1** is depicted in Scheme 3.



Scheme 3 Synthesis of compound 1.

### Preparation of test solution for UV-visible and fluorescence measurements

The UV-visible and fluorescence was recorded just after the addition of metal salts in ethanol solution, while keeping the ligand concentration constant ( $1 \times 10^{-5}$  mol dm $^{-3}$ ). The solution of metal ions were prepared from the sulfates salts of  $Zn^{2+}$ ,  $Fe^{2+}$ ,  $Al^{3+}$ ,  $Ca^{2+}$ ,  $Cu^{2+}$ ,  $Mg^{2+}$ ,  $Mn^{2+}$ ,  $Ni^{2+}$ , and  $Pb^{2+}$ . The blank solution was prepared just in HEPES buffer and without any added metal ion.

### Job's plot

The binding stoichiometry of sensor–metal complex was determined by the continuous variation method. From the stock solutions, various concentrations of  $Zn^{2+}$  viz.,  $1 \times 10^{-4}$ ,  $8 \times 10^{-6}$ ,  $4 \times 10^{-6}$ ,  $6 \times 10^{-5}$ ,  $4 \times 10^{-5}$ ,  $2 \times 10^{-6}$ ,  $8 \times 10^{-5}$ , and  $1 \times 10^{-5}$  mol dm $^{-3}$  were prepared and added to the solution of compound **1**. Each test solution had a total volume of 10 ml. After mixing for a few seconds, the fluorescence spectra were taken at 25 °C.

### Molecular modeling

Aiming to better understand the experimental measures, additional theoretical calculations have been conducted for the **1**– $Zn^{2+}$  and **1**– $Ca^{2+}$  complexes, the systems that exhibit the highest and smallest peaks in the fluorescence spectra, respectively (see Fig. 7 in discussion section). More specifically, the structures of both complexes are fully optimized within the density functional theory (DFT) framework. The M06-L/Def2-SVPD level of theory has been selected as it produces meaningful predictions on the Zn coordination chemistry.<sup>16</sup> Solvent effect are accounted for through the well-known polarizable continuum model (PCM)<sup>17</sup> considering water as solvent. Vibrational frequencies are subsequently computed with the same theoretical approach to ensure that the optimized structures correspond to minima in the potential energy surface (*i.e.* non-imaginary frequencies) as well as to obtain the free energies corrections. The equilibrium constants are computed by using the usual eqn (3):

$$K_{eq} = e^{-\Delta G^0/RT} \quad (3)$$

where  $R$  is the ideal gas constant,  $T$  is the temperature (298.15 K), and  $\Delta G^0$  is the standard Gibbs free energy obtained from the difference  $\Delta G^0$  of **1**– $Zn^{2+}$  and **1**– $Ca^{2+}$  complexes and the separate monomers (free forms of  $Zn^{2+}$ ,  $Ca^{2+}$  and **1** ligand). All calculations were performed with Gaussian09.<sup>18</sup>

The molecular docking protocol we have previously developed<sup>19</sup> for the study of the complexation processes between cyclodextrins and host molecules, was applied here for the investigation of the formation of the complex between  $\beta$ -cyclodextrin and **1**. The molecular structure used for  $\beta$ -cyclodextrin was extracted from the crystal structure of Protein Data Bank (PDB) with code 3CGT. Molecular docking calculations were carried out using default parameters in AutoDock Vina.<sup>20</sup> Graphical representations of the docking results were prepared using PyMOL (Molecular Graphics System, version 1.3, Schrödinger, LLC).

## Acknowledgements

This work was partially supported by the Fundación Séneca del Centro de Coordinación de la Investigación de la Región de Murcia under Project 18946/JLI/13, 19499-PI-14 and by the Nils Coordinated Mobility under grant 012-ABEL-CM-2014A, in part financed by the European Regional Development Fund (ERDF). “Powered@NLHPC: this research was partially supported by the supercomputing infrastructure of the NLHPC (ECM-02)”. Also, this work was partially supported by the computing facilities of Extremadura Research Centre for Advanced Technologies (CETA-CIEMAT), funded by the European Regional Development Fund (ERDF). CETA-CIEMAT belongs to CIEMAT and the Government of Spain. The authors also thankfully acknowledge the computer resources and the technical support provided by the Plataforma Andaluza de Bioinformática of the University of Málaga. P. M. S. K. is thankful to the Science and Engineering Research Board (SERB), Department of Science and Technology, India, for the financial support (Project Number SB/FT/CS-068/2012).

## References

- 1 A. I. Bush, W. H. Pettingell, G. Multhaup, M. Paradis, J.-P. Vonsattel, J. F. Gusella, K. Beyreuther, C. L. Masters and R. E. Tanzi, *Science*, 1994, **265**, 1464–1467.
- 2 M. D. Pluth, E. Tomat and S. J. Lippard, *Annu. Rev. Biochem.*, 2011, **80**, 333–335.
- 3 E. D. Gundelfinger, T. M. Boecheers, M. K. Baron and J. U. Bowie, *Trends Biochem. Sci.*, 2006, 366–373.
- 4 L. C. Costello, R. B. Franklin and P. Feng, *Mitochondrion*, 2005, **5**, 143–153.
- 5 S. L. Sensi, P. Paoletti, J. Y. Koh, E. Aizenman, A. Bush and M. Hershfinkel, *J. Neurosci.*, 2011, **31**, 16076–16085.
- 6 (a) S. K. Gosh, P. Kim, X. A. Zhang, S. H. Yun, A. Moore, S. J. Lippard and Z. Medarova, *Cancer Res.*, 2010, **70**, 6119–6127; (b) S. Tepaamorndech, L. Huang and C. P. Hirschke, *Cancer Lett.*, 2011, **308**, 33–42; (c) V. Kolenko, E. Teper, A. Kutikov and R. Uzzo, *Nat. Rev. Urol.*, 2013, **10**, 219–226.
- 7 (a) E. L. Que, D. W. Domaille and C. J. Chang, *Chem. Rev.*, 2008, **108**, 1517–1549; (b) P. Jiang and J. Guo, *Coord. Chem. Rev.*, 2004, **248**, 205–229; (c) P. Carol, S. Sreejith and A. Ajayagosh, *Chem.-Asian J.*, 2007, **2**, 338–348; (d) E. Kimura and S. Aoki, *BioMetals*, 2001, **14**, 191–204.
- 8 (a) I. V. M. V. Enoch and S. Yousuf, *J. Solution Chem.*, 2013, **42**, 470–484; (b) I. V. M. V. Enoch and M. Swaminathan, *Collect. Czech. Chem. Commun.*, 2004, **69**, 748–758.
- 9 S. Chandrasekaran, Y. Sameena and I. V. M. V. Enoch, *Aust. J. Chem.*, 2014, **67**, 256–265.
- 10 (a) M. Singh, S. K. Singh, M. Gangwar, G. Nath and S. K. Singh, *RSC Adv.*, 2014, **4**, 19013–19023; (b) N. P. Prajapati, R. H. Vekariya, M. A. Borad and H. D. Patel, *RSC Adv.*, 2014, **4**, 60176–60208; (c) Q. Lei, L. Zhang, Y. Xia, T. Ye, F. Yang, Y. Zhu, X. Song, N. Wang, Y. Xu, X. Liu and L. Yu, *RSC Adv.*, 2015, **5**, 41341–41351.
- 11 Y. Sameena, A. Ritty, P. M. Selvakumar, I. V. M. V. Enoch, P. S. Subramanian and Y. Sun, *ChemistryOpen*, 2015, **4**, 497–508.
- 12 H. A. Benesi and J. H. Hildebrand, *J. Am. Chem. Soc.*, 1949, **71**, 2703–2707.
- 13 (a) S. Chandrasekaran, Y. Sameena and I. V. M. V. Enoch, *J. Mol. Recognit.*, 2014, **27**, 640–652; (b) Y. Sameena, N. Sudha, S. Chandrasekaran and I. V. M. V. Enoch, *J. Biol. Phys.*, 2014, **40**, 347–367; (c) N. Sudha, S. Chandrasekaran, D. Premnath and I. V. M. V. Enoch, *Bull. Korean Chem. Soc.*, 2014, **35**, 2114–2122.
- 14 (a) V. K. Gupta, B. Sethi, R. A. Sharma, S. Agarwal and A. Bharti, *J. Mol. Liq.*, 2013, **177**, 114–118; (b) V. K. Gupta, A. K. Singh, M. Al Khayat and B. Gupta, *Anal. Chim. Acta*, 2007, **590**, 81–90; (c) A. K. Jain, V. K. Gupta, S. Radi, L. P. Singh and J. R. Raisoni, *Electrochim. Acta*, 2006, **51**, 2547–2553; (d) V. K. Gupta, A. K. Jain and P. Kumar, *Sens. Actuators, B*, 2006, **120**, 259–265; (e) V. K. Gupta, A. K. Jain, G. Maheshwari and H. Lang, *Sens. Actuators, B*, 2006, **117**, 99–106; (f) R. N. Goyal, V. K. Gupta and N. Bachheti, *Anal. Chim. Acta*, 2007, **597**, 82–89; (g) V. K. Gupta, S. Chandra and H. Lang, *Talanta*, 2005, **66**, 575–580; (h) R. Prasad, V. K. Gupta and A. Kumar, *Anal. Chim. Acta*, 2004, **508**, 61–70; (i) V. K. Gupta, R. Prasad and A. Kumar, *Talanta*, 2003, **60**, 149–160; (j) V. K. Gupta, S. Jain and S. Chandra, *Anal. Chim. Acta*, 2003, **486**, 199–207; (k) V. K. Gupta, S. Chandra and R. Mangla, *Electrochim. Acta*, 2002, **47**, 1579–1586; (l) V. K. Gupta, R. Mangla, U. Khurana and P. Kumar, *Electroanalysis*, 1999, **11**, 573–576; (m) V. K. Gupta, S. Jain and U. Khurana, *Electroanalysis*, 1997, **9**, 478–480.
- 15 Z. Xu, J. Yoon and D. R. Spring, *Chem. Soc. Rev.*, 2010, **39**, 996–2006.
- 16 O. Trott and A. J. Olson, *J. Comput. Chem.*, 2010, **31**, 455–461.
- 17 E. A. Amin and D. G. Truhlar, *J. Chem. Theory Comput.*, 2008, **4**, 75–85.
- 18 J. Tomasi, B. Mennucci and R. Cammi, *Chem. Rev.*, 2005, **105**, 2999–3093.
- 19 M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery Jr, J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazayev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox, *Gaussian 09 Revision A.02*, Gaussian Inc., Wallingford CT, 2009.
- 20 J. M. López-Nicolás, M. E. Camps, H. Pérez-Sánchez and F. García-Carmona, *J. Agric. Food Chem.*, 2013, **61**, 11347–11354.

